Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
AnGes Inc
Athira Pharma Inc
Beijing SH Bio-Tech Corp
Helixmith Co Ltd
i2 Pharmaceuticals Inc
Kringle Pharma Inc
Minerva Biotechnologies Corp
Molecular Partners AG
Yichang Humanwell Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
Ad-HGF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Lung Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDX-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones
Featured News & Press Releases
Feb 04, 2020: AnGes, Inc. initiated Phase 2b study in the U.S. in patients with lower limb ischemic ulcers
Dec 27, 2019: Molecular Partners receives orphan drug desigtion for MP0250 for multiple myeloma
Dec 20, 2019: Genopis, plasmid D manufacturer in San Diego, to Launch GMP contract manufacturing business
Dec 12, 2019: Molecular Partners provides update on its Multiple Myeloma drug candidate MP-0250 at R&D Day
Dec 09, 2019: Athira Pharma presents positive data for NDX-1017 in Alzheimer’s patients at 2019 clinical trials on Alzheimer’s disease (CTAD) conference
Dec 07, 2019: Molecular Partners presents updated results of MP0250 in patients with Relapsed/Refractory Multiple Myeloma (MM) at American Society of Hematology Annual Meeting
Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer’s Disease (CTAD) Conference
Oct 07, 2019: Helixmith shows long-term safety and efficacy of VM202 for painful DPN patients in DPN phase 3-1b extension study
Oct 02, 2019: Athira Pharma Announces Completion of Phase 1b Clinical Trial of NDX-1017 in Alzheimers Patients
Sep 23, 2019: Helixmith: Topline results of DPN Phase III study
Sep 04, 2019: Notice regarding the launch of Collategene intramuscular injection 4 mg, an HGF gene therapy product
Aug 02, 2019: Helixmith unveils results for neuromuscular disease treatment
Jul 16, 2019: Athira Pharma presents prelimiry results from phase 1 trial of NDX-1017 at Alzheimer’s Association Intertiol Conference 2019 (AAIC)
May 27, 2019: Yooyoung Pharmaceutical: YYB101 -- refractory solid tumor treatment
May 01, 2019: Athira Pharma announces appointment of Dr. Hans J. Moebius as chief medical officer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AnGes Inc, H1 2020
Pipeline by Athira Pharma Inc, H1 2020
Pipeline by Beijing SH Bio-Tech Corp, H1 2020
Pipeline by Helixmith Co Ltd, H1 2020
Pipeline by i2 Pharmaceuticals Inc, H1 2020
Pipeline by Kringle Pharma Inc, H1 2020
Pipeline by Minerva Biotechnologies Corp, H1 2020
Pipeline by Molecular Partners AG, H1 2020
Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
Pipeline by Yooyoung Pharm Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020